{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-076714","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.468710+00:00","generated_at":"2026-06-17T21:17:33.622585+00:00","sec_items":["2.01","3.01","9.01","3.02","3.03","5.01","5.02","5.03","8.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"CalciMedica closes reverse merger with Graybug; Nasdaq delisting notice received for failing initial listing criteria","bullets":["Merger closed March 20, 2023; 3.95M shares issued to CalciMedica stockholders; CalciMedica equityholders own ~72% of combined company.","Company renamed CalciMedica, Inc.; ticker changes to CALC on March 21, 2023, but Nasdaq staff determined it fails initial listing requirements.","Nasdaq suspension scheduled for March 30; Company will appeal and intends to trade on OTCQB if unsuccessful.","New board and executive team from CalciMedica: CEO A. Rachel Leheny, COO Michael Dunn, CFO Daniel Geffken; prior Graybug CEO and CFO terminated.","Pre-merger private placement raised $10.3M from ~20.7M shares of CalciMedica common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-076714","json":"https://secwatch.observer/filing/0001193125-23-076714.json","markdown":"https://secwatch.observer/filing/0001193125-23-076714.md","text":"https://secwatch.observer/filing/0001193125-23-076714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:17:33.622585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"232329366326f765c4f1ca0bfb9b18a9ca6a04df","claim":"CalciMedica, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5110(a), 5405(b)(2)(A), 5405(b)(2)(C)).","evidence_excerpt":"March 21, 2023, the Company received written notice (the “Notice”) from the Staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Staff has determined that the Company has not complied with the requirements of Nasdaq Listing Rule 5110(a) because the Company did not demonstrate compliance with all of the requirements for initial listing on Nasdaq concurrent with closing the merger transaction. Specifically, the Company did not meet the minimum stockholders’ equity requirement pursuant to Nasdaq Listing Rule 5405(b)(2)(A), the Mar","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5110(a), 5405(b)(2)(A), 5405(b)(2)(C)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"00c890242a","claim":"Christy Shaffer resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"36c3f750ef","claim":"Eric Bjerkholt resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"468b68deda","claim":"Julie Eastland resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"67abac8a62","claim":"Christina Ackermann resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6cdd9b4245","claim":"Dirk Sauer resigned as Director at CalciMedica, Inc..","evidence_excerpt":"each of Eric Bjerkholt, Christy Shaffer, Ph.D., Christina Ackermann, Julie Eastland and Dirk Sauer, Ph.D., resigned from Graybug’s board of directors and any respective committee membership of Graybug’s board of directors, effective as of the effective time of Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"714ec1d577","claim":"Allan Shaw was appointed as Class III Director at CalciMedica, Inc..","evidence_excerpt":"Allan Shaw 59 Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"7f3eeb0c70","claim":"Eric Bjerkholt was appointed as Class I Director at CalciMedica, Inc..","evidence_excerpt":"Eric Bjerkholt was reappointed to the Company’s board of directors as a Class I director, effective as of the effective time of the Merger.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"834433eb5c","claim":"A. Rachel Leheny was appointed as Chief Executive Officer and Class II Director at CalciMedica, Inc..","evidence_excerpt":"A. Rachel Leheny, Ph.D. 59 Chief Executive Officer and Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Class II Director"}],"fact_type":"executive_change"},{"claim_id":"91f42665d7","claim":"Fred Middleton was appointed as Class I Director at CalciMedica, Inc..","evidence_excerpt":"Fred Middleton 73 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"9907720555","claim":"Eric W. Roberts was appointed as Chief Business Officer and Class II Director at CalciMedica, Inc..","evidence_excerpt":"Eric W. Roberts 59 Chief Business Officer and Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Business Officer and Class II Director"}],"fact_type":"executive_change"},{"claim_id":"af9d338f76","claim":"Robert S. Breuil was terminated as Chief Financial Officer at CalciMedica, Inc..","evidence_excerpt":"each of Frederic Guerard, PharmD., Graybug’s President and Chief Executive Officer, and Robert S. Breuil, Graybug’s Chief Financial Officer, were terminated effective as of the effective time of the Merger.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"be64ea053f","claim":"Sudarshan Hebbar was appointed as Chief Medical Officer at CalciMedica, Inc..","evidence_excerpt":"Sudarshan Hebbar, M.D. 58 Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"c24460ed4a","claim":"Parisa Zamiri was terminated as other_named_officer at CalciMedica, Inc..","evidence_excerpt":"on February 28, 2023, the board of directors of Graybug terminated Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.7,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"}],"fact_type":"executive_change"},{"claim_id":"c2e453a99f","claim":"Michael J. Dunn was appointed as President and Chief Operating Officer at CalciMedica, Inc..","evidence_excerpt":"Michael J. Dunn, MBA 67 President and Chief Operating Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"c5ad91403f","claim":"Frederic Guerard was terminated as President and Chief Executive Officer at CalciMedica, Inc..","evidence_excerpt":"each of Frederic Guerard, PharmD., Graybug’s President and Chief Executive Officer, and Robert S. Breuil, Graybug’s Chief Financial Officer, were terminated effective as of the effective time of the Merger.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d870069cac","claim":"Kenneth A. Stauderman was appointed as Chief Scientific Officer at CalciMedica, Inc..","evidence_excerpt":"Kenneth A. Stauderman, Ph.D. 70 Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"e1e192cf16","claim":"Daniel Geffken was appointed as Interim Chief Financial Officer at CalciMedica, Inc..","evidence_excerpt":"Daniel Geffken, MBA 66 Interim Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e1f0108ede","claim":"Frederic Guerard was appointed as Class II Director at CalciMedica, Inc..","evidence_excerpt":"Frederic Guerard, Pharm.D. 50 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"f7b8abe034","claim":"Robert N. Wilson was appointed as Chair of the Board and Class III Director at CalciMedica, Inc..","evidence_excerpt":"Robert N. Wilson 82 Chair of the Board and Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board and Class III Director"}],"fact_type":"executive_change"},{"claim_id":"72440d4c9c6b3734d50063a5e61396852a8461cd","claim":"CalciMedica, Inc.: Certificate of Amendment filed to change company name from Graybug Vision, Inc. to CalciMedica, Inc (effective 2023-03-20).","evidence_excerpt":"Immediately prior to the consummation of the Merger, on March 20, 2023, Graybug filed the Certificate of Amendment changing its name from “Graybug Vision, Inc.” to “CalciMedica, Inc.”","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-20"}],"fact_type":"governance_change"},{"claim_id":"e8c00a4027f63511094b4e0459608812e69b55b3","claim":"CalciMedica, Inc. underwent a change of control involving CalciMedica, Inc. (closed 2023-03-20).","evidence_excerpt":"On March 20, 2023, Graybug, Merger Sub and CalciMedica consummated the transactions contemplated by the Merger Agreement following the Special Meeting.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/0001193125-23-076714-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"CalciMedica, Inc."},{"label":"Closing","value":"2023-03-20"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}